Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression — Stella

Home/SSTR Positive Tumors/

View on ClinicalTrials.gov

Recruiting

Back to SSTR Positive Tumors trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chao Yang

Key details

Phase

Safety & dosing / Large-scale testing

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrollment target

~400 participants

Started

December 2022

Primary completion

December 2028

Age range

18 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.